Institute of Pharmacology and Toxicology, University Hospital, Friedrich Schiller University, Jena, Germany.
Br J Pharmacol. 2011 Sep;164(2):298-307. doi: 10.1111/j.1476-5381.2011.01382.x.
Morphine activates the µ-opioid receptor without causing its rapid endocytosis. In contrast, full agonists such as [d-Ala(2) -MePhe(4) -Gly-ol]enkephalin (DAMGO) or etonitazene stimulate a rapid and profound internalization. However, the detailed molecular events underlying the differential regulation of receptor trafficking by distinct opioid agonists remain incompletely understood.
Here, we have generated phosphosite-specific antibodies for the carboxyl-terminal residues serine 363 (Ser363), threonine 370 (Thr370) and serine 375 (Ser375), which enabled us to selectively detect either the Ser363-, Thr370- or Ser375-phosphorylated form of the receptor.
We showed that agonist-induced phosphorylation occurs at Thr370 and Ser375, whereas Ser363 is constitutively phosphorylated in the absence of agonist. We further demonstated that DAMGO and etonitazene stimulated the phosphorylation of both Thr370 and Ser375. In contrast, morphine promoted the phosphorylation of Ser375, but failed to stimulate Thr370 phosphorylation. In the presence of DAMGO, Ser375 phosphorylation occurred at a faster rate than phosphorylation of Thr370, indicating that Ser375 is the primary site of agonist-dependent phosphorylation. Activation of PKC by phorbol 12-myristate 13-acetate increased receptor phosphorylation only on Thr370, but not on Ser375, indicating that Thr370 can also undergo heterologous PKC-mediated phosphorylation. We also showed that µ receptor dephosphorylation can occur within minutes at or near the plasma membrane, and that agonist removal is a major prerequisite for Thr370 and Ser375 dephosphorylation.
Together, we showed for the first time that distinct agonists stimulate site-specific patterns of phosphorylation, which are intimately related to their ability to elicit µ-opioid receptor sequestration.
This article is commented on by Kelly, pp. 294-297 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476-5381.2011.01387.x.
吗啡激活μ阿片受体而不引起其快速内吞。相比之下,完全激动剂,如[d-Ala(2)-MePhe(4)-Gly-ol]enkephalin(DAMGO)或依托尼秦,刺激快速而深刻的内化。然而,不同阿片类激动剂对受体运输的差异调节的详细分子事件仍不完全了解。
在这里,我们生成了羧基末端残基丝氨酸 363(Ser363)、苏氨酸 370(Thr370)和丝氨酸 375(Ser375)的磷酸化特异性抗体,使我们能够选择性地检测受体的 Ser363-、Thr370-或 Ser375-磷酸化形式。
我们表明,激动剂诱导的磷酸化发生在 Thr370 和 Ser375,而 Ser363 在没有激动剂的情况下是组成性磷酸化的。我们进一步证明 DAMGO 和依托尼秦刺激 Thr370 和 Ser375 的磷酸化。相比之下,吗啡促进 Ser375 的磷酸化,但未能刺激 Thr370 的磷酸化。在 DAMGO 的存在下,Ser375 的磷酸化发生速度比 Thr370 的磷酸化更快,表明 Ser375 是激动剂依赖性磷酸化的主要位点。佛波醇 12-肉豆蔻酸 13-乙酸酯激活 PKC 仅增加 Thr370 上的受体磷酸化,而不是 Ser375 上的磷酸化,表明 Thr370 也可以发生异源 PKC 介导的磷酸化。我们还表明,μ 受体去磷酸化可以在几分钟内在质膜或质膜附近发生,并且激动剂去除是 Thr370 和 Ser375 去磷酸化的主要前提条件。
总的来说,我们首次表明,不同的激动剂刺激特定部位的磷酸化模式,这与它们引起μ阿片受体隔离的能力密切相关。
本文由 Kelly 在本期的第 294-297 页进行了评论。要查看此评论,请访问 http://dx.doi.org/10.1111/j.1476-5381.2011.01387.x。